| Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. | leukemia, |
| ID4 gene might be inactivated by DNA hypermethylation, and may function as a tumor suppressir gene in malignant lymphoma | lymphoma, |
| ID4 is a novel tumour suppressor gene in normal human breast tissue and is epigenetically silenced during cancer development, indicating increased risk for tumour relapse. | breast, |
| these results demonstrate loss of Id4 expression in prostate cancer due to promoter hypermethylation. The data strongly support the role of Id4 as a tumor suppressor. | prostate, |
| ID4 acts as a tumor suppressor in prostate cancer, and its loss promotes castration-resistant prostate cancer through constitutive androgen receptor activation. | prostate, |
| Hypermethylation of ID4 promotes the proliferation of Burkitt_s lymphoma cells; ID4 may function as a tumor suppressor and can be targeted with demethylating compounds such as CdR for the treatment of Burkitt_s lymphoma | lymphoma, |
| Data propose that ID4 is frequently silenced by promoter methylation in ER+ breast cancers and functions as a tumor suppressor gene in these tumors, probably due to its interaction with key genes of the ER pathway. | breast, |
| ID4 gene is a potential tumor suppressor gene for which methylation status may play an important role in the CRC progression | None |
| These findings indicate that ID4 acts as a tumour suppressor in myeloid malignancies, and ID4 methylation is a potential biomarker in predicting disease progression and treatment outcome. | None |